| scholarly article | Q13442814 |
| P50 | author | Antoni X Torres-Collado | Q55080080 |
| P2093 | author name string | Ali R Jazirehi | |
| James S Economou | |||
| Ramin Nazarian | |||
| P2860 | cites work | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | Q27851698 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. | Q33906093 | ||
| Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells | Q34069302 | ||
| Resistance to BRAF Inhibition in Melanomas | Q34166376 | ||
| Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses | Q34650346 | ||
| Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs | Q36028423 | ||
| BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy | Q36175312 | ||
| A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. | Q36926465 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma | Q37727061 | ||
| Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy | Q37777312 | ||
| Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights | Q37982476 | ||
| Resistance to BRAF-targeted therapy in melanoma | Q38071800 | ||
| Update on the Targeted Therapy of Melanoma | Q38082713 | ||
| What is new in the treatment of advanced melanoma? State of the art. | Q38116006 | ||
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
| Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction | Q39619870 | ||
| MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. | Q39630026 | ||
| RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations | Q39803993 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells | Q40262620 | ||
| Role of epidermal growth factor receptor signaling in RAS-driven melanoma | Q40427048 | ||
| Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis | Q40594629 | ||
| Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells | Q53302291 | ||
| Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling | Q58450931 | ||
| P433 | issue | 1 | |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 43-56 | |
| P577 | publication date | 2014-02-27 | |
| P1433 | published in | American journal of clinical and experimental immunology | Q27724357 |
| P1476 | title | Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor | |
| P478 | volume | 3 |
| Q33436058 | A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. |
| Q92257010 | Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment |
| Q37641527 | Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function |
| Q64105358 | Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies |
| Q36414039 | Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells |
| Q97074415 | Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma |
| Q26783032 | Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy |
| Q47225796 | Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors |
| Q27329598 | Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse |
| Q57066104 | Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo |
| Q47135020 | Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade |
Search more.